27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Shares of Amgen (NASDAQ:AMGN) were flat in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share rose 7.05% year over year to $4.25, which beat the estimate of $3.84.
Revenue of $6,206,000,000 rose by 5.71% year over year, which beat the estimate of $6,180,000,000.
Outlook
Earnings guidance hasn't been issued by the company for now.
Amgen hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: Jul 28, 2020
Time: 05:00 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/zu6j6vvu
Technicals
52-week high: $264.97
52-week low: $173.12
Price action over last quarter: Up 12.56%
Company Description
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and received approval for bone-strengthening drug Prolia/Xgeva in 2010. Amgen's acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering) and Aimovig (migraine).
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!